STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

Marjolaine Debant (1) , Miguel Burgos (1) , Patrice Hémon (1) , Paul Buscaglia (1) , Tinhinane Fali (1) , Sarra Melayah (1, 2) , Nelig Le Goux (1) , Christophe Vandier (3, 4) , Marie Potier-Cartereau (3, 4) , Jacques-Olivier Pers (1) , Christian Berthou (1, 5) , Cristina Bagacean (1, 2, 5) , Olivier Mignen (1, 4) , Yves Renaudineau (6, 1, 4)

1 LBAI - Lymphocytes B, Autoimmunité et Immunothérapies
2 Laboratoire d'Immunologie et Immunothérapie [Brest]
3 N2Cox - Niche, Nutrition, Cancer et métabolisme oxydatif
4 Cancéropôle Grand-Ouest
5 CHU-Brest-Hemato - CHRU Brest - Service d'Hématologie
6 Laboratoire d'Immunologie et Immunothérapie

Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance of the newly described constitutive Ca2+ entry (CE) pathway is less clear. In addition, we hypothesized that these differences reflect modifications of the CE pathway and Ca2+ actors such as Orai1, transient receptor potential canonical (TRPC) 1, and stromal interaction molecule 1 (STIM1), the latter being the focus of this study.

Mots clés: CLL; Constitutive Ca2+ entry; Disease outcome; STIM1

Domaines: Sciences du Vivant [q-bio]

Marjolaine Debant, Miguel Burgos, Patrice Hémon, Paul Buscaglia, Tinhinane Fali, et al.. STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia. Journal for Immunotherapy of Cancer, 2019, 7 (1), pp.111. ⟨10.1186/s40425-019-0591-3⟩. ⟨hal-02114358⟩